SABRAC is an inhibitor of acid ceramidase (IC50 = 52 nM).1 It is selective for acid ceramidase over neutral ceramidase and the cysteine protease papain at 3 µM. SABRAC inhibits acid ceramidase in PC3 MC metastatic prostate cancer cells (IC50 = <1 µM), as well as induces accumulation of ceramides in the same cells. It completely inhibits anchorage-independent colony formation but does not induce cytotoxicity in PC3 MC cells when used at a concentration of 5 µM.
1.Camacho, L., Meca-CortÉs, O., Abad, J.L., et al.Acid ceramidase as a therapeutic target in metastatic prostate cancerJ. Lipid Res.54(5)1207-1220(2013)